Gene signature combinations improve prognostic stratification of multiple myeloma patients

[1]  G. Mulligan,et al.  Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. , 2015, Blood.

[2]  H. Goldschmidt,et al.  IMWG consensus on risk stratification in multiple myeloma , 2014, Leukemia.

[3]  G. Mulligan,et al.  A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma , 2013, PloS one.

[4]  H. Goldschmidt,et al.  Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project , 2013, Leukemia.

[5]  Sean R. Davis,et al.  NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..

[6]  Gareth J. Morgan,et al.  A gene expression signature for high-risk multiple myeloma , 2012, Leukemia.

[7]  John Crowley,et al.  Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. , 2011, Blood.

[8]  J. San-Miguel,et al.  Can multiple myeloma become a curable disease? , 2011, Haematologica.

[9]  T. Rème,et al.  A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines , 2011, Haematologica.

[10]  Arnoldo Frigessi,et al.  Combining Gene Signatures Improves Prediction of Breast Cancer Survival , 2011, PloS one.

[11]  T. Rème,et al.  Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma , 2011, Haematologica.

[12]  G. Morgan,et al.  Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome , 2010, Clinical Cancer Research.

[13]  Crispin J. Miller,et al.  Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene , 2010, British Journal of Cancer.

[14]  M. Abba,et al.  Breast Cancer Biomarker Discovery in the Functional Genomic Age: A Systematic Review of 42 Gene Expression Signatures , 2010, Biomarker insights.

[15]  Carlos Caldas,et al.  A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer , 2008, Breast Cancer Research.

[16]  Laurence Lodé,et al.  Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Sotiriou,et al.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2008, Breast Cancer Research.

[18]  B. Barlogie,et al.  Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2 , 2008, British journal of haematology.

[19]  Ahmet Dogan,et al.  The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. , 2008, Blood.

[20]  R. Bataille,et al.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[21]  Anthony Boral,et al.  Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.

[22]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[23]  R. Tibshirani,et al.  Prediction by Supervised Principal Components , 2006 .

[24]  R. Fonseca,et al.  Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Tibshirani,et al.  Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data , 2004, PLoS biology.

[28]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[29]  R. Fonseca.  Strategies for risk-adapted therapy in myeloma. , 2007, Hematology. American Society of Hematology. Education Program.